Key facts
- This page summarizes James G. Liddy's Form 4 filing for Hepion Pharmaceuticals, Inc. (HEPA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Aug 2026, 16:30.
James G. Liddy - 19 Aug 2026 Form 4 Insider Report for Hepion Pharmaceuticals, Inc. (HEPA)
- Reporting relationship
- Director
- Issuer ticker
- HEPA
- Reported as of
- 19 Aug 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Aug 2026, 16:30:07 UTC
- Prior SEC filing
- 05 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ James G. Liddy
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
James G. Liddy filed Form 4 for Hepion Pharmaceuticals, Inc. (HEPA) on 21 Aug 2026.
Change
- Previous filing in this sequence was filed on 05 Nov 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002082917
Primary reporting owner
Liddy James Gordon
- Relationship
- Director
- Address
- C/O HEPION PHARMACEUTICALS, INC., 34 SHREWSBURY AVE., SUITE 1D, RED BANK,
- Signature
- /s/ James G. Liddy
- Signature date
- 21 Aug 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HEPA
transaction
Derivative
Stock Options
Award
- Transaction value
- Shares
- +299,000
- Change %
- Price
- $0.000000*
- Shares after
- 299,000
- Date
- 19 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 299,000
- Exercise price
- $0.0800
* marks a reported price that did not pass the local price check.